CD8A and neoplasm: In addition, this inhibitor combined with an anti-PD1 antibody markedly improved the survival and the levels of lymphocytes infiltrating the tumor (CD8+ T cells), as early as 15 days after treatment, resulting in a significant reduction in tumor mass [141].